What does this research mean for the field?

Nimotuzumab combined with concurrent chemoradiotherapy provides high objective response rates and promising survival with tolerable toxicity in patients with postoperative loco-regional recurrent esophageal squamous cell carcinoma. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy of nimotuzumab combined with concurrent chemoradiotherapy in patients with postoperative recurrent esophageal squamous cell carcinoma.

May 29, 2026Journal of Clinical Oncology

Efficacy of nimotuzumab combined with concurrent chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal squamous cell carcinoma: A phase II study.

View Full Paper

Ask AI

Bookmark

Authors

JZJialiang ZhouNantong University JWJia WuWuxi Fourth People's Hospital TYTianqi YangJiangnan University

Discussion

Member takes

Implication

Phase II study finds nimotuzumab with chemoradiotherapy improves responses in recurrent esophageal cancer, suggesting potential benefits.

Key Points

To evaluate the efficacy of nimotuzumab combined with concurrent chemoradiotherapy in patients with postoperative recurrent esophageal squamous cell carcinoma.
Single-arm phase II study involving 42 patients aged 18-75 with postoperative recurrent esophageal squamous cell carcinoma.
Nimotuzumab was administered in combination with CCRT using a TP chemotherapy regimen and specific radiotherapy dosing.
Primary endpoint was objective response rate, with secondary endpoints including overall survival and disease control rate.
Objective response rate was 85.71% with 12 (28.57%) complete responses and 24 (57.14%) partial responses.
3-year overall survival was 51.8% (95% CI: 36.9-72.8%), while 3-year progression-free survival was 33.4% (95% CI: 20.4-54.7%).
Tolerable toxicity profile with common adverse events including leukopenia and radiation esophagitis; no serious adverse events related to nimotuzumab.

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/6a192d2efab5b468c441602f https://doi.org/10.1200/jco.2026.44.16_suppl.4067

View Full Paper

Ask AI

Bookmark

Efficacy of nimotuzumab combined with concurrent chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal squamous cell carcinoma: A phase II study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of nimotuzumab combined with concurrent chemoradiotherapy for patients with postoperative loco-regional recurrent esophageal squamous cell carcinoma: A phase II study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider